COVID-19 outcome is not affected by anti-CD20 or high-titer convalescent plasma in immunosuppressed patients

The role of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) convalescent plasma in the treatment of Coronavirus Disease 2019 (COVID-19) in immunosuppressed individuals remains controversial. We describe the course of COVID-19 in patients who had received anti-CD20 therapy within the 3 y...

Descripción completa

Detalles Bibliográficos
Autores principales: Kasten, Mary J., Lahr, Brian D., Parisapogu, Anusha, Yetmar, Zachary A., O’Horo, John C., Orenstein, Robert, Moreno Franco, Pablo, Razonable, Raymund R., Vergidis, Paschalis, Shah, Aditya S., Enzler, Mark J., Inwards, David J., Bauer, Philippe R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10692159/
https://www.ncbi.nlm.nih.gov/pubmed/38040756
http://dx.doi.org/10.1038/s41598-023-48145-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10692159/
https://www.ncbi.nlm.nih.gov/pubmed/38040756
http://dx.doi.org/10.1038/s41598-023-48145-x

Ejemplares similares